News
-
-
-
PRESS RELEASE
Lenzing with revenue and earnings growth in first half of the year – tariff policy slows recovery momentum
Lenzing reports revenue and earnings growth in first half of 2025 despite challenges from tariff measures. Implementation of performance program boosts EBITDA and secures financing until 2027 -
PRESS RELEASE
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées et une mise à jour des caractéristiques du produit
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées et une mise à jour des caractéristiques du produit -
PRESS RELEASE
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
Valneva announces FDA's removal of recommended pause on Chikungunya Vaccine IXCHIQ® in elderly individuals and updates to the Prescribing Information, following EMA's recommendation. Updates reflect Serious Adverse Events and expanded Warnings and Precaution section -
PRESS RELEASE
9 Months: Economic weakness and geopolitical environment pose temporary challenges // Comprehensive pipeline underpins strong positioning in the SAP market // Revised forecast confirmed
All for One Group SE faces temporary challenges in weak economy and geopolitical environment with revised forecast confirmation. 9-month figures show slight revenue growth and focus on SAP market positioning -
-
-
-
PRESS RELEASE
Brockhaus Technologies AG: Publication of the audited annual financial statements; revenue increases in 2024 by +9.5% to €204 million and adjusted EBITDA by +4.5% to €65 million.
Brockhaus Technologies AG reports +9.5% revenue growth in 2024 to €204 million and +4.5% increase in adjusted EBITDA to €65 million. Company outlook for 2025 revealed
